Latest news
{{'2025-09-17T21:05:17Z' | dateFormatFilter}}
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
{{'2025-09-16T10:00:47Z' | dateFormatFilter}}
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
{{'2025-09-15T22:03:35Z' | dateFormatFilter}}
People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being
Progress towards zero environmental impact
Being respected for adding value to society
Ensure distinct core capabilities and evolve culture
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD
Strengthen Diabetes leadership - aim at global value market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Deliver solid sales and operating profit growth:
- Deliver 6-10% sales growth in International Operations
- Transform 70% of sales in the USA1
Drive operational efficiencies across the value chain to enable investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Investors
Share price
{{priceData.date}} {{priceData.time}}